169 reports of this reaction
1.7% of all VARENICLINE reports
#18 most reported adverse reaction
EPISTAXIS is the #18 most commonly reported adverse reaction for VARENICLINE, manufactured by Oyster Point Pharma, Inc.. There are 169 FDA adverse event reports linking VARENICLINE to EPISTAXIS. This represents approximately 1.7% of all 10,186 adverse event reports for this drug.
Patients taking VARENICLINE who experience epistaxis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EPISTAXIS is a less commonly reported adverse event for VARENICLINE, but still significant enough to appear in the safety profile.
In addition to epistaxis, the following adverse reactions have been reported for VARENICLINE:
The following drugs have also been linked to epistaxis in FDA adverse event reports:
EPISTAXIS has been reported as an adverse event in 169 FDA reports for VARENICLINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EPISTAXIS accounts for approximately 1.7% of all adverse event reports for VARENICLINE, making it a notable side effect.
If you experience epistaxis while taking VARENICLINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.